3.03

5.90% -0.19

Pre-market: 3.02 -0.010 -0.33%

Cyclerion Therapeutics Inc (CYCN)

Overview News Price History Financials Discussions Forecast Stock Split

Cyclerion Therapeutics Inc stock is traded at $3.03, with a volume of 182.90K. It is down -5.90% in the last 24 hours and up +108.97% over the past month. Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. The company focuses on enabling the full therapeutic potential of next-generation sGC stimulators and neuropsychiatric diseases. Its pipeline products include Olinciguat, Praliciguat, and others.

Previous Close:

$3.22

Open:

$3.16

24h Volume:

182.90K

Relative Volume:

0.04

Market Cap:

$13.12M

Revenue:

$2.07M

Net Income/Loss:

$-3.53M

P/E Ratio:

-2.5759

EPS:

-1.1763

Net Cash Flow:

$-3.31M

1W Performance:

+4.84%

1M Performance:

+108.97%

6M Performance:

+27.85%

1Y Performance:

+12.64%

1-Day Range:

$2.9804

$3.3802

1-Week Range:

$2.80

$3.75

52-Week Range:

$1.0266

$8.48

Cyclerion Therapeutics Inc Stock (CYCN) Company Profile

Name

Cyclerion Therapeutics Inc

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

617-621-7722

Address

301 BINNEY STREET, CAMBRIDGE, MA

Employee

Twitter

@Cyclerion

Next Earnings Date

2026-03-31

Latest SEC Filings

CYCN's Discussions on Twitter

Compare CYCN vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CYCN Cyclerion Therapeutics Inc	3.03	13.12M	2.07M	-3.53M	-3.31M	-1.1763
VRTX Vertex Pharmaceuticals Inc	441.70	112.35B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	753.93	79.71B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	840.87	52.29B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	333.39	44.48B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	319.94	35.51B	5.36B	287.73M	924.18M	2.5229

Cyclerion Therapeutics Inc Stock (CYCN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-20-21	Initiated	Truist	Buy
Sep-24-21	Initiated	Cantor Fitzgerald	Overweight
Jun-03-19	Initiated	Credit Suisse	Neutral

Cyclerion Therapeutics Inc Stock (CYCN) Latest News

Apr 13, 2026

Published on: 2026-04-13 23:21:17 - baoquankhu1.vn

Apr 13, 2026

Guidance Update: Is Cyclerion Therapeutics Incs growth already priced inEarnings Recap Summary & Fast Entry Momentum Alerts - baoquankhu1.vn

Apr 13, 2026

Apr 09, 2026

CYCN stock is soaring 150% pre-market today — what is fueling the rally? - MSN

Apr 09, 2026

Are UNF, NSA, CYCN, ULYX Obtaining Fair Deals for their Shareholders? - Finviz

Apr 09, 2026

Fed Watch: Is Cyclerion Therapeutics Incs growth already priced inQuarterly Earnings Summary & AI Optimized Trade Strategies - baoquankhu1.vn

Apr 09, 2026

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Cyclerion Therapeutics, Inc. (Nasdaq – CYCN), National Storage Affiliates (NYSENSA), Urgent.ly, Inc. (OTC MarketsULYX), UniFirst Corporation (NYSEU - ChartMill

Apr 09, 2026

12 Health Care Stocks Moving In Tuesday's After-Market Session - Sahm

Apr 09, 2026

Apr 08, 2026

Rate Hike: Is Cyclerion Therapeutics Incs growth already priced in2026 Historical Comparison & Expert Approved Momentum Ideas - baoquankhu1.vn

Apr 08, 2026

Apr 07, 2026

Halper Sadeh LLC is Investigating Whether SLNO, FORA, MKC, CYCN are Obtaining Fair Deals for their Shareholders - GlobeNewswire Inc.

Apr 07, 2026

Apr 06, 2026

Alzheimer’s company Korsana heads to NASDAQ via merger: Deals Report - biocentury.com

Apr 06, 2026

CYCN Stock Price, Quote & Chart | CYCLERION THERAPEUTICS INC (NASDAQ:CYCN) - ChartMill

Apr 06, 2026

Apr 05, 2026

Penny stock CYCN surged more than 300% yesterday. Why, and should you chase the rally here? - MSN

Apr 05, 2026

Globalstar, Exxon Mobil, Cyclerion Therapeutics, Eli Lilly And Intel: Why These 5 Stocks Are On Investors' Radars Today - Sahm

Apr 03, 2026

SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) - Sahm

Apr 03, 2026

Apr 02, 2026

Korsana Biosciences and Cyclerion Therapeutics Announce All-Stock Merger and $380 Million Financing - Global Legal Chronicle

Apr 02, 2026

Monteverde & Associates Investigates Cyclerion Therapeutics Merger - National Today

Apr 02, 2026

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire

Apr 02, 2026

CYCN Plunges 17% After Merger Announcement: What’s Next for Cyclerion and Korsana? - Bitget

Apr 02, 2026

Cyclerion and Korsana Tie the Knot with a New Merger Strategy - StocksToTrade

Apr 02, 2026

Cyclerion Therapeutics Merger Sparks Investor Uncertainty - timothysykes.com

Apr 02, 2026

Penny Stock CYCN Surged More Than 300% Yesterday. Why, And Should You Chase the Rally Here? - Barchart.com

Apr 02, 2026

Korsana boosts Alzheimer’s work with reverse merger, $380M financing - BioWorld News

Apr 02, 2026

CYCN Stock Alert: Halper Sadeh LLC is Investigating Whether Cycle - The National Law Review

Apr 02, 2026

Cyclerion Therapeutics and Korsana Biosciences Announce $380M Merger to Advance Alzheimer’s Treatment KRSA-028 - Minichart

Apr 02, 2026

CYCN Stock Explodes 313% on April 1 After Cyclerion-Korsana Merger Deal for Alzheimer's Pipeline - International Business Times Australia

Apr 02, 2026

12 Health Care Stocks Moving In Wednesday's Intraday Session - Sahm

Apr 02, 2026

CYCN Stock Alert: Halper Sadeh LLC is Investigating Whether Cyclerion Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders - The Joplin Globe

Apr 02, 2026

Apr 01, 2026